Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer

Tokyo, Basking Ridge, N.J. and Munich– (September 14, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials